Statements (83)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:DNA
|
gptkbp:associated_with |
gptkb:chronic_myeloid_leukemia
gptkb:Oncology gptkb:sports_equipment gptkb:guidelines treatment adherence clinical trials community outreach patient outcomes patient registries public health initiatives research funding supportive care disease progression epidemiological studies treatment response cell signaling pathways genomic studies epigenetic changes genetic counseling oncogenes precision medicine international guidelines tyrosine kinase activity patient monitoring therapeutic resistance survivorship issues imatinib resistance clinical trials design myeloproliferative disorders leukemogenesis clonal evolution relapse rates |
gptkbp:can_detect |
PCR
FISH |
gptkbp:cause |
gptkb:fusion
|
gptkbp:discovered_by |
gptkb:1973
|
https://www.w3.org/2000/01/rdf-schema#label |
Philadelphia chromosome
|
gptkbp:influences |
treatment options
|
gptkbp:involves |
chromosome 9
chromosome 22 t(9;22)(q34;q11) |
gptkbp:involves_gene |
gptkb:ABL1
BCR |
gptkbp:is_found_in |
gptkb:hematopoietic_stem_cells
|
gptkbp:is_linked_to |
gptkb:scientific_collaborations
gptkb:Health_Insurance palliative care patient education quality of life advocacy efforts data sharing genetic testing health disparities multidisciplinary teams family history biostatistics healthcare costs risk stratification survival rates targeted therapy tumor suppressor genes molecular genetics chromosomal translocation therapeutic targets genetic instability increased cell proliferation long-term outcomes poor prognosis research advancements clinical management inhibition of apoptosis biological markers biomarker development molecular monitoring secondary mutations |
gptkbp:is_recognized_as |
gptkb:Philadelphia,_Pennsylvania
|
gptkbp:is_recognized_by |
cytogenetic analysis
|
gptkbp:is_targeted_at |
tyrosine kinase inhibitors
|
gptkbp:resulted_in |
gptkb:BCR-ABL_fusion_protein
|
gptkbp:bfsParent |
gptkb:chronic_myeloid_leukemia
gptkb:Oncology |
gptkbp:bfsLayer |
4
|